Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

Q: Context: Elements form compounds when they combine chemically. Their atoms join together to form molecules, crystals, or other structures. The atoms are held together by chemical bonds. A chemical bond is a force of attraction between atoms or ions. It occurs when atoms share or transfer valence electrons. Valence electrons are the electrons in the outer energy level of an atom. You can learn more about chemical bonds in this video: MEDIA Click image to the left or use the URL below. URL: Look at the example of water in Figure 7.1. A water molecule consists of two atoms of hydrogen and one atom of oxygen. Each hydrogen atom has just one electron. The oxygen atom has six valence electrons. In a water molecule, two hydrogen atoms share their two electrons with the six valence electrons of one oxygen atom. By sharing electrons, each atom has electrons available to fill its sole or outer energy level. This gives it a more stable arrangement of electrons that takes less energy to maintain. Water (H2 O) is an example of a chemical compound. Water molecules always consist of two atoms of hydrogen and one atom of oxygen. Like water, all other chemical compounds consist of a fixed ratio of elements. It doesnt matter how much or how little of a compound there is. It always has the same composition. Elements are represented by chemical symbols. Examples are H for hydrogen and O for oxygen. Compounds are represented by chemical formulas. Youve already seen the chemical formula for water. Its H2 O. The subscript 2 after the H shows that there are two atoms of hydrogen in a molecule of water. The O for oxygen has no subscript. When there is just one atom of an element in a molecule, no subscript is used. Table 7.1 shows some other examples of compounds and their chemical formulas. Name of Compound Electron Dot Diagram Numbers of Atoms Chemical Formula Name of Compound Hydrogen chloride Electron Dot Diagram Numbers of Atoms H=1 Cl = 1 Chemical Formula HCl Methane C=1 H=4 CH4 Hydrogen peroxide H=2 O=2 H2 O2 Carbon dioxide C=1 O=2 CO2 Problem Solving Problem: A molecule of ammonia consists of one atom of nitrogen (N) and three atoms of hydrogen (H). What is its chemical formula? Solution: The chemical formula is NH3 . You Try It! Problem: A molecule of nitrogen dioxide consists of one atom of nitrogen (N) and two atoms of oxygen (O). What is its chemical formula? The same elements may combine in different ratios. If they do, they form different compounds. Figure 7.2 shows some examples. Both water (H2 O) and hydrogen peroxide (H2 O2 ) consist of hydrogen and oxygen. However, they have different ratios of the two elements. As a result, water and hydrogen peroxide are different compounds with different properties. If youve ever used hydrogen peroxide to disinfect a cut, then you know that it is very different from water! Both carbon dioxide (CO2 ) and carbon monoxide (CO) consist of carbon and oxygen, but in different ratios. How do their properties differ? There are different types of compounds. They differ in the nature of the bonds that hold their atoms together. The type of bonds in a compound determines many of its properties. Three types of bonds are ionic, covalent, and metallic bonds. You will read about these three types in later lessons. You can also learn more about them by watching this video: (7:18). MEDIA Click image to the left or use the URL below. URL: Chocolate: Its been revered for millennia by cultures throughout the world. But while its easy to appreciate all of its delicious forms, creating this confection is a complex culinary feat. Local chocolate makers explain the elaborate engineering and chemistry behind this tasty treat. And learn why its actually good for your health! For more information on the science of chocolate, see [Link] . MEDIA Click image to the left or use the URL below. URL: 
 Question: force of attraction between atoms or ions that share or transfer electrons

A: chemical bond
****
Q: Context: It is unanimously accepted that there is an unmet need for pain medications that are both effective and safe. Unfortunately, no really novel analgesics have been approved over the past three decades. In view of both experimental and clinical evidence of a major role for nerve growth factor (NGF) in the generation and maintenance of a wide range of pain states, drug discovery efforts focusing on the development of anti-NGF agents have aroused particular interest. Several humanized anti-NGF monoclonal antibodies (mAbs) have entered clinical trials as potential analgesics. In this respect, tanezumab is at an advanced stage of clinical development while fulranumab, fasinumab and ABT-110, previously known as PG110, are in early phases of clinical development. This Current Opinion article aims at describing the rationale for targeting NGF for pain, reviewing the analgesic efficacy and safety of anti-NGF agents based on data from fully published studies, conference abstracts, and the US Food and Drug Administration (FDA) website, and discussing the possible future of these agents in managing chronic pain. Anti-NGF mAbs produced significant pain relief and functional improvement in patients with osteoarthritis of the knee and/or hip. Conversely, studies in non-specific lower back pain generated mixed results; overall, this condition appeared to be less responsive to anti-NGF agents than osteoarthritis. Finally, there was no conclusive evidence of the effectiveness of anti-NGF mAbs in some types of chronic visceral or neuropathic pain. Furthermore, these studies raised safety concerns about anti-NGF mAbs. As a class, these drugs may cause or worsen peripheral neuropathies. But the most problematic issue-which prompted the FDA to place studies of these compounds on clinical hold in 2010-was rapid joint destruction leading to joint replacement surgery. The aetiologies of these side effects have been much debated and their pathophysiology is poorly understood. After an Arthritis Advisory Committee meeting held in March 2012, pharmaceutical companies negotiated with the FDA on the conditions for restarting clinical studies. Although the FDA lifted its clinical hold, there remain many unresolved issues about the long-term efficacy and safety of anti-NGF mAbs. While acknowledging that the future of these drugs is unforeseeable, it appears that they may not be the safe and effective painkillers that have been awaited for decades. 
 Question: What is the target of tanezumab?

A: ngf
****
Q: Context: Highly conserved sequences at the 5' splice site and branch site of U12-dependent introns are important determinants for splicing by U12-dependent spliceosomes. This study investigates the in vivo splicing phenotypes of mutations in the branch site consensus sequence of the U12-dependent intron F from a human NOL1 (P120) minigene. Intron F contains a fully consensus branch site sequence (UUCCUUAAC). Mutations at each position were analyzed for their effects on U12-dependent splicing in vivo. Mutations at most positions resulted in a significant reduction of correct U12-dependent splicing. Defects observed included increased unspliced RNA levels, the activation of cryptic U2-dependent 5' and 3' splice sites, and the activation of cryptic U12-dependent branch/3' splice sites. A strong correlation was observed between the predicted thermodynamic stability of the branch site: U12 snRNA interaction and correct U12-dependent splicing. The lack of a polypyrimidine tract between the branch site and 3' splice site of U12-dependent introns and the observed reliance on base-pairing interactions for correct U12-dependent splicing emphasize the importance of RNA/RNA interactions during U12-dependent intron recognition and proper splice site selection. 
 Question: Which is the branch site consensus sequence in U12-dependent introns?

A:
uuccuuaac
****